Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE（PATH-STROKE）
Objectives of Study:To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic cerebral infarction under the guidance of platelet aggregation function.
- EligibilityCriteria: Inclusion Criteria:  Aged from 18 to 80 years; Patients with non-cardiogenic cerebral infarction WHO meet the definition of stroke, who have been ruled out hemorrhagic stroke by head CT or MRI examination and identified as ischemic stroke; The onset of first stroke >=1 month; mRS Score <=2 points; Mab platelet therapy with aspirin 100mg qd for >=14 days; Informed consent signed by the patient or legal representative.  Exclusion Criteria:  History of gastrointestinal bleeding, intracranial bleeding, and other hemorrhagic diseases; Contraindications or intolerances to the use of antiplatelet therapy drugs; Patients with severe heart, lung, liver and renal insufficiency and with serious co-existing diseases (such as tumor, chronic airflow disease, severe dementia, and severe heart failure; Poor compliance, unable to cooperate with the completion of research requirements. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult